Although surgical resection and target therapy can improve the prognosis of some LUAD patients, LUAD is still the most mortality disease worldwide. And the small number of useful biomarker makes it challenging to the diagnose and treatment of LUAD at early stage and predict therapeutic effects. Therefore, exploring the novel biomarkers and understanding the mechanism of metastasis of LUADA may provide new tools to treat the disease.
Recently, dysregulated expression of ncRNAs (circRNAs, lncRNAs, miRNAs) was found to be correlated with tumorigenesis and the progression of cancers, whilst the functions of most of these ncRNAs are still a mystery due to the limitation of detection technique and useful databases. Over the traditional sequencing technology, NGS allows us to find novel ncRNAs and to identify tumor driver genes in several types of cancer [15, 16]. In this study, it is the first comprehensive NGS analysis of transcripts profiles including ncRNAs and mRNAS of the development of LUAD, including the non-nodal metastasis LUAD samples, lymph node metastasis LUAD samples, and healthy cohorts. Through comprehensively selected, we found that 75 dif-mRNAs, 880 dif-circRNAs, 125 dif-miRNAs in non-nodal metastasis LUAD samples compared with controls, which supposed to be associated with the pathogenesis of LUAD. Further, the enriched genes in the ceRNA networks that is relevant to the pathological process of LUAD, included regulation of biological process, regulation of cellular process, as well as various pathways, such as Hippo signaling pathway and microRNAs in cancer. One of these networks involves the gene IREB2, a master regulator of iron metabolism that mediates iron uptake, metabolism and storage.
Ferroptosis, a novel form of iron dysregulation induced cell death, is crucial in regulating growth of tumors, such as colorectal cancer, hepatocellular carcinoma, pancreatic cancer, and NSCLC [17–19]. Previous research has suggested that ncRNAs and endogenous ceRNA network mediated ferroptosis drives the lung carcinogenesis. For example, LINC00336 functions as an oncogene to facilitate tumor cell proliferation, inhibit ferroptosis in an ELAVL1-dependent manner in lung cancer [20]; lncRNA P53RRA acts as a potential tumor suppressor by dissociating p53 from a cytosolic Ras GTPase-activating protein-binding protein 1 (G3BP1) complex, inducing cell-cycle arrest and ferroptosis [21]; moreover, lncRNA-MT1DP enhanced the sensitivity NSCLC cells to eartin-induced ferroptosis by regulating the miR-365a-3p/NRF2 signaling pathways[22]. In mammals, iron regulatory proteins (IRPs) post-transcriptionally regulate iron levels by binding to iron responsive elements (IREs). As the iron sensor, IREB2 directly binds to the RNA stem-loop structures in the 3’-untranslated region (UTR) of mRNA and stabilizes transcripts of iron transporters, such as transferrin receptor protein 1 (TFRC), thereby increasing intracellular iron concentration[23, 24]. Song et. al suggested that activation of IREB2-TFRC pathway increases intracellular iron concentration and enhances cell sensitivity to ferroptosis and reinforces host antitumor immunity[25]. In this study, NGS data indicated the expression of IREB2 was significantly downregulated in non-nodal metastasis LUAD samples compared with controls; similarity, the same lower levels of this gene was validated in 16 more LUAD specimens. Thereby, we hold the hypothesis that the dysregulation of IREB2-associated ferroptosis might one of the occurrence factors of LUAD; however, whether it is connected with the metastasis and poor survival needs further study.
Additionally, we found the significant role of upregulated hsa-miR-6509-3p, has-miR-6511a-3p, and has-miR-6803-3p in the mentioned sixteen LUAD samples. Evidence has shown that miR-6509 serves as tumor-suppressive miRNA in cancer. Fan et al. reported that lncRNA SNHG6 acted as a ceRNA of miR-6509 for promoting cell proliferation in hepatocellular carcinoma [26]. In this study, miR-6509-3p was found to be in the center of the ceRNA network in the pathogenesis of LUAD and the target miRNA of IREB2. Hence, miR-6803-3p and miR-6511a-3p were both upregulated in LUAD and shared the binding sites with IREB2, which was consent with the results of miR-6509-3p; however, the role of these two miRNAs was still unclear. Plausibly, miR-6509-3p, miR-6511a-3p, miR-6803-3p may play an important role in the pathogenesis of LUAD. Further mechanistic studies are warranted to determine the miRNA-IREB2 axis in LUAD.